Teva swoops on Auspex with $3.2bn acquisition
This article was originally published in Scrip
Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals in an all cash deal valuing the CNS-focused firm at $3.2bn. Teva executives underlined that the deal did not preclude other, bigger, deals that it is still hoping to make.
You may also be interested in...
FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone to these conditions.
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Biopharma executives see value-based pricing as an increasingly important topic for the sector in 2023, while the US Inflation Reduction Act will have a major impact on portfolio strategies.